Alzamend Neuro, Inc. ALZN
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -15.93%
- 1 year
- -39.04%
- Market cap
- 7.38M
- EPS (ttm)
- -2.30
- Shares out
- 5.43M
- Forward P/E
- -0.26
- YTD return
- -15.93%
- 1-year return
- -39.04%
- Volume
- 71.33K
- Avg volume
- 81.23K
- Open
- 1.55
- Previous close
- 1.46
- Day's range
- 1.48 – 1.62
- 52-week range
- 0.84 – 2.61
- Beta
- -0.04
- Analysts
- Strong Buy
- Price target
- 32.00 (+1991.5%)
- Earnings date
- Sep 11, 2024
2Y -13.27 (-89.36%)
Key statistics
- Enterprise value
- 3.47M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.36M
- Total cash
- 1.19M
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 3.11%
- 50-day average
- 1.42
- 200-day average
- 4.08
Analyst view
Consensus: strong buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Sep 11, 2024
Expected Sep 11, 2024. Consensus EPS estimate -0.29.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 11, 2024 | Oct 1, 2024 | -2.38 | -0.40 | +1.98 | +83.19% |
| Sep 11, 2024 | Jul 1, 2024 | 0.00 | -1.25 | — | — |
| Sep 11, 2024 | Jul 1, 2024 | 0.00 | — | — | — |
| Mar 25, 2024 | Jan 1, 2024 | 0.00 | — | — | — |
| Mar 25, 2024 | Jan 1, 2024 | 0.00 | -3.80 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | Ascendiant Capital | main | Buy | Buy |
| Nov 11, 2024 | Ascendiant Capital | main | Buy | Buy |
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alzamend.com
News
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock? 
Alzamend Neuro Regains Nasdaq Compliance 
Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY 
Alzamend Neuro Announces Its Abstract On Resting-State Functional Magnetic Resonance Imaging Findings For AL001 Accepted For Presentation At Neuroscience 2026 
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC 
Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday 
Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26 - Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
Your note
Sign in to keep a note on ALZN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AULT MILTON C III | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 18, 2024 | 0 |
| GUSTAFSON MARK GARLAND | Director | Sale | Mar 30, 2022 | 60,000 |
| HORNE WILLIAM B | Director | Conversion of Exercise of derivative security | Feb 23, 2023 | 1,000,000 |
| JACKMAN STEPHAN | Chief Executive Officer | Purchase | Apr 27, 2023 | 45,500 |
| KATZOFF DAVID J | Chief Financial Officer | Purchase | Sep 25, 2023 | 81,000 |
| MCGRATH LYNNE FAHEY | Director | Sale | Dec 25, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Susquehanna International Group, LLP | 0.31% | 16,601 | 19.75K | Sep 29, 2024 |
| Truist Financial Corp | 0.29% | 15,498 | 18.44K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.08% | 4,167 | 4.96K | Sep 29, 2024 |
| Blackrock Inc. | 0.07% | 3,973 | 4.73K | Sep 29, 2024 |
| Wells Fargo & Company | 0.02% | 1,000 | 1.19K | Sep 29, 2024 |
| Corecap Advisors, LLC | 0.01% | 708 | 842 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.14% | 7,854 | 9.35K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.07% | 3,848 | 4.58K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 2,189 | 2.60K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 999 | 1.19K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.01% | 705 | 838 | Oct 30, 2024 |